Given the role of GM-CSF in inflammatory diseases, GM-CSF -blocking therapies are currently in clinical trials in patients with rheumatoid arthritis and multiple sclerosis.38, 39, 40. This evidence concerns the gene CSF2 and multiple sclerosis.